{"id":"https://openalex.org/W2071494467","doi":"https://doi.org/10.1021/jm020951i","title":"Design and Synthesis of Plasmepsin I and Plasmepsin II Inhibitors with Activity in Plasmodium falciparum-Infected Cultured Human Erythrocytes","display_name":"Design and Synthesis of Plasmepsin I and Plasmepsin II Inhibitors with Activity in Plasmodium falciparum-Infected Cultured Human Erythrocytes","publication_year":2003,"publication_date":"2003-01-22","ids":{"openalex":"https://openalex.org/W2071494467","doi":"https://doi.org/10.1021/jm020951i","mag":"2071494467","pmid":"https://pubmed.ncbi.nlm.nih.gov/12593654"},"language":"en","primary_location":{"id":"doi:10.1021/jm020951i","doi":"https://doi.org/10.1021/jm020951i","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm020951i","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066930684","display_name":"Daniel N\u00f6teberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I4210088043","display_name":"Medivir (Sweden)","ror":"https://ror.org/002jks503","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210088043"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Daniel N\u00f6teberg","raw_affiliation_strings":["Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden","institution_ids":["https://openalex.org/I123387679","https://openalex.org/I28166907","https://openalex.org/I4210088043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078930676","display_name":"Elizabeth Hamelink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I4210088043","display_name":"Medivir (Sweden)","ror":"https://ror.org/002jks503","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210088043"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Elizabeth Hamelink","raw_affiliation_strings":["Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden","institution_ids":["https://openalex.org/I123387679","https://openalex.org/I28166907","https://openalex.org/I4210088043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025869348","display_name":"Johan Hult\u00e9n","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I4210088043","display_name":"Medivir (Sweden)","ror":"https://ror.org/002jks503","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210088043"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Johan Hult\u00e9n","raw_affiliation_strings":["Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden","institution_ids":["https://openalex.org/I123387679","https://openalex.org/I28166907","https://openalex.org/I4210088043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044797922","display_name":"Mats Wahlgren","orcid":"https://orcid.org/0000-0001-6541-6056","observed_orcids":["https://orcid.org/0000-0001-6541-6056"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I4210088043","display_name":"Medivir (Sweden)","ror":"https://ror.org/002jks503","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210088043"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Mats Wahlgren","raw_affiliation_strings":["Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden","institution_ids":["https://openalex.org/I123387679","https://openalex.org/I28166907","https://openalex.org/I4210088043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086480661","display_name":"Lotta Vrang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I4210088043","display_name":"Medivir (Sweden)","ror":"https://ror.org/002jks503","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210088043"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Lotta Vrang","raw_affiliation_strings":["Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden","institution_ids":["https://openalex.org/I123387679","https://openalex.org/I28166907","https://openalex.org/I4210088043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112790292","display_name":"Bertil Samuelsson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I4210088043","display_name":"Medivir (Sweden)","ror":"https://ror.org/002jks503","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210088043"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Bertil Samuelsson","raw_affiliation_strings":["Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden","institution_ids":["https://openalex.org/I123387679","https://openalex.org/I28166907","https://openalex.org/I4210088043"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108389244","display_name":"Anders Hallberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I4210088043","display_name":"Medivir (Sweden)","ror":"https://ror.org/002jks503","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210088043"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anders Hallberg","raw_affiliation_strings":["Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Organic Pharmaceutical Chemistry, Uppsala University, Box 574, SE \u2212 751 23 Uppsala, Sweden, Medivir AB, Lunastigen 7, SE \u2212 141 44 Huddinge, Sweden, and Karolinska Institute, MTC, Box 280, SE \u2212 171 77 Stockholm, Sweden","institution_ids":["https://openalex.org/I123387679","https://openalex.org/I28166907","https://openalex.org/I4210088043"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":11.9515,"has_fulltext":false,"cited_by_count":87,"citation_normalized_percentile":{"value":0.98717949,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"46","issue":"5","first_page":"734","last_page":"746"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10091","display_name":"Malaria Research and Control","score":0.9740999937057495,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10091","display_name":"Malaria Research and Control","score":0.9740999937057495,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10620","display_name":"Protease and Inhibitor Mechanisms","score":0.02019999921321869,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12685","display_name":"Phytochemical compounds biological activities","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/plasmepsin-ii","display_name":"plasmepsin II","score":1.0},{"id":"https://openalex.org/keywords/plasmodium-falciparum","display_name":"Plasmodium falciparum","score":0.9100000262260437},{"id":"https://openalex.org/keywords/protease-inhibitors","display_name":"protease inhibitors","score":0.921999990940094},{"id":"https://openalex.org/keywords/antimalarial-drugs","display_name":"antimalarial drugs","score":0.7580000162124634},{"id":"https://openalex.org/keywords/enzyme-selectivity","display_name":"enzyme selectivity","score":0.828000009059906},{"id":"https://openalex.org/keywords/cathepsin-d","display_name":"cathepsin D","score":0.9190000295639038},{"id":"https://openalex.org/keywords/parasite-growth-inhibition","display_name":"parasite growth inhibition","score":0.847000002861023},{"id":"https://openalex.org/keywords/infected-red-blood-cells","display_name":"infected erythrocytes","score":0.8529999852180481}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6831080317497253},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.6410379409790039},{"id":"https://openalex.org/C180000673","wikidata":"https://www.wikidata.org/wiki/Q899268","display_name":"Isostere","level":2,"score":0.6079787015914917},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.581565797328949},{"id":"https://openalex.org/C2778371730","wikidata":"https://www.wikidata.org/wiki/Q311383","display_name":"Plasmodium falciparum","level":3,"score":0.574446976184845},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.5381733775138855},{"id":"https://openalex.org/C173633252","wikidata":"https://www.wikidata.org/wiki/Q3663475","display_name":"Cathepsin D","level":3,"score":0.5381579995155334},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4850703775882721},{"id":"https://openalex.org/C2780034444","wikidata":"https://www.wikidata.org/wiki/Q5052485","display_name":"Cathepsin L","level":4,"score":0.4146495461463928},{"id":"https://openalex.org/C167844969","wikidata":"https://www.wikidata.org/wiki/Q426245","display_name":"Cathepsin","level":3,"score":0.38515400886535645},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20549684762954712},{"id":"https://openalex.org/C2778048844","wikidata":"https://www.wikidata.org/wiki/Q12156","display_name":"Malaria","level":2,"score":0.15424013137817383},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002478","descriptor_name":"Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004912","descriptor_name":"Erythrocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D004912","descriptor_name":"Erythrocytes","qualifier_ui":"Q000469","qualifier_name":"parasitology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010963","descriptor_name":"Plasmodium falciparum","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015800","descriptor_name":"Protozoan Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016282","descriptor_name":"Aspartic Acid Endopeptidases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1021/jm020951i","doi":"https://doi.org/10.1021/jm020951i","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm020951i","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:12593654","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12593654","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8048999905586243,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W1979196526","https://openalex.org/W2001304056","https://openalex.org/W2007845287","https://openalex.org/W2062937488","https://openalex.org/W2071582487","https://openalex.org/W2090178505","https://openalex.org/W2093094597","https://openalex.org/W2105668259","https://openalex.org/W2128378359","https://openalex.org/W2165174924","https://openalex.org/W2949740906","https://openalex.org/W2951811260","https://openalex.org/W4253865610"],"related_works":["https://openalex.org/W1991380804","https://openalex.org/W1974040456","https://openalex.org/W2040164972","https://openalex.org/W2132694815","https://openalex.org/W1996665221","https://openalex.org/W2156105675","https://openalex.org/W2811001408","https://openalex.org/W3037967150","https://openalex.org/W2902037851","https://openalex.org/W2058998489"],"abstract_inverted_index":{"A":[0,46,79],"series":[1],"of":[2,53,60,106,112],"protease":[3],"inhibitors":[4,108],"targeted":[5],"at":[6],"the":[7,28,34,54,61,68,73,107],"malarial":[8],"enzymes":[9],"plasmepsin":[10],"I":[11],"and":[12,14,33,117],"II,":[13],"encompassing":[15],"a":[16],"basic":[17],"hydroxyethylamine":[18],"transition":[19],"state":[20],"isostere":[21],"scaffold,":[22],"was":[23,102],"prepared.":[24],"The":[25],"substituents":[26],"in":[27,38,89],"P1'":[29],"position":[30],"were":[31,83],"varied":[32],"biological":[35],"activities":[36],"expressed":[37],"K(i)-values":[39],"ranged":[40],"from":[41],"60":[42],"to":[43,85],">2000":[44],"nM.":[45],"more":[47],"than":[48],"4-fold":[49],"selectivity":[50],"for":[51,67,104],"either":[52],"plasmepsins":[55,69],"could":[56],"be":[57],"achieved.":[58],"All":[59],"active":[62,81],"compounds":[63,82],"exhibited":[64],"high":[65],"preference":[66],"over":[70],"cathepsin":[71],"D,":[72],"most":[74],"closely":[75],"related":[76],"human":[77,92],"protease.":[78],"few":[80],"shown":[84],"inhibit":[86],"parasite":[87],"growth":[88],"cultured":[90],"infected":[91],"erythrocytes.":[93],"An":[94],"ED(50)":[95],"value":[96],"as":[97,99],"low":[98],"1.6":[100],"microM":[101],"observed":[103],"one":[105],"despite":[109],"K(i)":[110],"values":[111],"115":[113],"nM":[114,119],"(Plm":[115,120],"I)":[116],"121":[118],"II).":[121]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}